Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is making significant strides in its transition from a development-stage biotechnology company to a commercial-stage entity, underscored by the FDA approval and subsequent commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). The company's strategic focus on first-in-class critical care products has positioned it to address substantial unmet medical needs across oncology, anti-infectives, and prescription therapeutics.
LYMPHIR™, approved by the U.S. Food and Drug Administration in August 2024, is a targeted immunotherapy for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The commercial launch in December 2025 has already generated $5.6 million in net product revenue during the first six months of fiscal 2026, with gross margins of approximately 80%. Broad payer coverage, nearly 100% of covered commercial lives, and formulary inclusion for 83% of targeted accounts as of May 2026, indicate strong market acceptance. The company has also initiated international expansion with an initial shipment to Europe in April 2026.
Beyond LYMPHIR™'s approved indication, Citius is exploring its potential in other oncology settings. Investigator-initiated studies have evaluated LYMPHIR™ in combination with pembrolizumab for recurrent or refractory gynecologic cancers and prior to CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma. Positive topline results from both Phase 1 studies were reported in fiscal 2026, suggesting broader applicability.
The company's late-stage pipeline includes Mino-Lok®, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). These infections are particularly serious in cancer and hemodialysis patients. Mino-Lok® met primary and secondary endpoints in its pivotal Phase 3 superiority trial and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. The company holds worldwide rights through a license from The University of Texas MD Anderson Cancer Center. Following a Type C meeting, the FDA provided guidance outlining a pathway to support a future New Drug Application submission. The potential worldwide sales are estimated at approximately $1.8 billion.
Another promising candidate is Halo-Lido (CITI-002), a proprietary topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. With an estimated 10 million people in the U.S. reporting hemorrhoid symptoms annually, and no FDA-approved prescription products currently available, Halo-Lido could become the first such product. The Phase 2b study completed in 2023, and the company has met with the FDA to discuss next steps.
Citius is also developing a stem cell platform based on induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. Interim results from a proof-of-concept sheep model showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls.
The company's experienced leadership, including CEO Leonard Mazur with five decades in the pharmaceutical industry, and Executive Vice Chairman Myron Holubiak, former president of Roche Laboratories, provides strong guidance. This combination of a revenue-generating commercial product and multiple clinical-stage programs offers several potential catalysts for future development and value creation.
Citius Pharmaceuticals is positioning itself as a key player in critical care, with LYMPHIR™ already contributing to revenue and a pipeline that addresses significant unmet needs. The company's progress underscores its potential to deliver innovative therapies to patients and create value for shareholders.
